【摘要】 目的　研究卵巢癌组织中 p2 1表达及其预后意义。方法　采用免疫组化检测 75例卵巢癌组织中 p2 1、p5 3表达情况 ,结合临床病理因素探讨 p2 1表达与卵巢癌预后的关系。结果　 (1) p2 1与 p5 3表达与不相关 (P=0 .197) ;(2 )p2 1高表达率为 6 1.33% (46 /75 ) ,它与年龄、腹水、FIGO分期、病理类型、分化程度、残瘤大小、初复治等临床病理因素不相关 ;(3)多因素分析表明残留大小 (P=0 .0 316 )、p2 1表达 (P=0 .0 172 )、FIGO分期 (P=0 .0 198)是独立的危险因素。尤其在初治病例中 ,p2 1高表达者预后差。结论　 p2 1表达可作为卵巢癌初治患者新的预后指标而指导临床治疗更多还原

【Abstract】 Objective The study the p21 WAF1 protein expression and its prognostic value in ovarian carcinoma. Methods By using immunohistochemical staining, p21 WAF1 and p53 protein expression in a series of 75 ovarian carcinomas was investigated to determine their relationship to the outcome of ptients in combine with the clinical and pathological features. Results (1) No correlation was found between p21 expression and p53 expression ( P =0.197). (2) High level expression of p21 was detected in 61.33 % of patients, but no statistically significant difference was found in the p21 expression with age、 ascites、 FIGO staging、pathological type、differentiation、the amount of the residual disease、initially treated or retreated cases. (3) Multivariate survival analysis identified the amount of the residual disease ( P =0 0316)、 p21 expression ( P =0 0172)、 FIGO staging ( P =0 0198) as independent risk variables. High levels of p21 correlated with poor prognosis, especially in the initial treated cases.Conclusion p21 is suggested as a new prognostic factor for the initially treated patients with ovarian carcinoma, and would be helpful in planning the treatment.更多还原